Core Insights - Nanox Imaging Ltd has entered into a distribution agreement with Althea France to introduce its CE-marked Nanox.ARC system in the French healthcare sector, marking its fourth distribution agreement in Europe [1][2][3] Company Overview - Nanox is focused on advancing medical imaging technology, aiming to drive the transition to preventive healthcare through affordable solutions that leverage AI and proprietary digital X-ray sources [4][5] Partnership Details - Althea France will manage the market introduction, sales, and service of the Nanox.ARC, which is a multi-source digital tomosynthesis system designed to enhance diagnostic capabilities at a lower cost compared to traditional systems [2][3] - The partnership is expected to leverage Althea's established relationships with hospitals and clinics across France, facilitating the introduction of Nanox's imaging platform [3] Market Strategy - France is identified as a strategic market for Nanox, with the partnership expected to expand access to high-quality, affordable imaging services for patients [3] - The collaboration follows previous agreements in Greece, Romania, and the Czech Republic, indicating a growing presence in the European market [1][2]

Financial Data and Key Metrics Changes - The company reported a GAAP net loss of $13.7 million for Q3 2025, compared to a net loss of $13.6 million in Q3 2024 [31] - Revenue for Q3 2025 was $3.4 million, an increase from $3.0 million in the comparable period [31] - Non-GAAP gross loss for the reported period was $0.3 million, compared to a gross loss of $0.2 million in the comparable period, representing a gross loss margin of approximately 8% [32] Business Line Data and Key Metrics Changes - Revenue from teleradiology services for Q3 2025 was $3.1 million, with a gross profit of $0.1 million, compared to revenue of $2.6 million and a gross profit of $0.3 million in the comparable period [32] - Revenue from the sale and deployment of imaging systems and OEM services amounted to $175,000 for the reported period, with a gross loss of $1.7 million [35] - Revenue from AI solutions for the reported period was $0.1 million, with a gross loss of $1.9 million [35] Market Data and Key Metrics Changes - The company is expanding its presence in Europe with new agreements in the Czech Republic and France, indicating rising demand for its imaging ecosystem [7][15] - The company aims to deploy 100 systems worldwide by the end of 2025, with several systems pending regulatory approval [7] Company Strategy and Development Direction - The company is focused on building a comprehensive medical imaging portfolio, reinforcing its position in the medical AI sector, and deepening its foothold in the U.S. healthcare system [4][5] - The acquisition of VasoHealthcare IT is intended to enhance customer service and expand the company's operational capabilities [10][22] - The company is preparing to launch the next-generation Nanox.ARC X system, which is designed to meet diverse clinical needs and expand the addressable market [8][9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving over $35 million in revenues for 2026, driven by strategic partnerships and the acquisition of VasoHealthcare IT [5][39] - The company anticipates that the AI business segment will achieve EBITDA break-even on a quarterly basis in 2026, while the overall company aims for break-even in 2027 [30][62] Other Important Information - The company has a strong presence planned at the RSNA annual meeting, where it will provide insights into its commercial progress and future strategy [13][21] - The company is actively engaged in clinical trials to support the use of its solutions in lung cancer detection and management [18][20] Q&A Session Summary Question: How many systems were in the field and performing scans that resulted in your revenue of $175,000? - The CEO mentioned that a few dozen systems were deployed, with some pending installation and regulatory approvals [44] Question: What types of agreements should we be thinking about in terms of those being lease versus capital sales? - The CFO indicated that the majority of agreements are expected to be MSES, with some CapEx sales anticipated [48] Question: Could you talk about how OpEx could look over the next four to six quarters? - Management indicated that sales and marketing expenses will increase due to deployment efforts, while R&D expenses will be more controlled [56] Question: Could you talk about Vaso and the types of customers they currently have? - The CEO stated that Vaso's customers are primarily medical-related, serving hospitals and imaging centers, presenting cross-selling opportunities [58] Question: Could you reiterate the break-even expectations for the AI business and ARC division? - Management reiterated that the AI business is expected to reach quarterly break-even in 2026, while the ARC division aims for break-even in 2027 [60][62]

Core Insights - Perimeter Medical Imaging AI, Inc. is participating in the "Take the Lead in Breast Cancer Care" summit, which gathers leading breast cancer physicians to discuss advancements in patient care [1][3] - The company's S-Series OCT technology, which received FDA clearance in 2021, allows surgeons to visualize margins during surgery, and an AI-assisted version is currently under FDA evaluation [2][4] Company Overview - Perimeter Medical Imaging AI is based in Toronto and Dallas, focusing on transforming cancer surgery with advanced imaging tools that provide real-time, ultra-high-resolution visualization of excised tissues at the cellular level [4] - The Perimeter S-Series OCT system is FDA-cleared and available across the U.S., while the investigational Perimeter B-Series OCT with ImgAssist AI is undergoing a pivotal clinical trial supported by a grant of up to US$7.4 million from the Cancer Prevention and Research Institute of Texas [4][5] Industry Context - The summit features multi-disciplinary discussions among surgeons, oncologists, pathologists, and genetic specialists, aimed at exploring innovative diagnostics and therapeutic discoveries to improve patient outcomes [3]

Core Insights - Perimeter Medical Imaging AI, Inc. is showcasing its S-Series OCT technology for real-time margin visualization during breast conserving surgery at the 2025 Annual Clinical Assembly [1][2][3] Company Overview - Perimeter Medical Imaging AI is a commercial-stage medical technology company based in Toronto and Dallas, focused on transforming cancer surgery with advanced imaging tools [4] - The S-Series OCT system has received FDA clearance in 2021 and provides real-time, cross-sectional visualization of excised tissues at the cellular level [4] - The investigational Perimeter B-Series OCT with ImgAssist AI is currently under evaluation in a pivotal clinical trial, supported by a grant of up to US$7.4 million from the Cancer Prevention and Research Institute of Texas [4] Technology and Application - Dr. Amelia Tower's presentation emphasizes the importance of advanced imaging technologies like the S-Series OCT in reducing re-excision rates and enhancing surgical precision [3][2] - The S-Series OCT allows surgeons to visualize disease at the cellular level in real-time, potentially reducing the stress and delays associated with re-excisions [3] Event Participation - The 2025 Annual Clinical Assembly, sponsored by the American College of Osteopathic Surgeons, gathers over 1,200 multi-disciplinary surgeons for networking and continuing medical education [3]

Core Insights - Nanox Imaging Ltd has announced a collaboration with Monarch Medical Management and Billing LLC to deploy advanced imaging solutions across various healthcare segments, including workers' compensation, nursing homes, and outpatient clinics [1][2][4] Group 1: Collaboration Details - The collaboration aims to establish a comprehensive imaging network by deploying Nanox's technology across Monarch's associated healthcare facilities, with over a dozen initial sites identified for a proof-of-concept phase [2] - Nanox's advanced imaging services will be accessible to patients in multiple care settings, including the Nanox.ARC system, AI-powered software for analyzing CT scans, and teleradiology services [3][4] Group 2: Strategic Goals - The collaboration addresses critical imaging access challenges by providing faster access to high-quality imaging services, which can accelerate accurate diagnosis and treatment decisions for patients [4] - Nanox's vision includes expanding its technology reach beyond hospital settings, aiming for a seamless end-to-end solution from scan to diagnosis, leveraging AI for improved efficiency in medical imaging [6] Group 3: Company Background - Nanox is focused on transitioning the world to preventive healthcare through affordable medical imaging technologies based on advanced AI and proprietary digital X-ray sources [5] - The Nanox ecosystem includes various components such as Nanox.ARC, Nanox.AI, Nanox.CLOUD, and Nanox.MARKETPLACE, all aimed at enhancing early detection and treatment to improve health outcomes globally [6]

Core Insights - Izotropic Corporation is initiating strategic awareness initiatives in anticipation of the commercialization of its IzoView Breast CT Imaging System, which aims to enhance breast cancer screening and diagnosis [1][2]. Group 1: Awareness Campaign - The awareness efforts will focus on educating global audiences about the transformative value of dedicated breast CT technology, highlighting IzoView's unique features and competitive advantages [2][5]. - The campaign will incorporate emerging trends in breast imaging, regulatory frameworks, and market growth forecasts to contextualize IzoView's potential [2]. Group 2: Communication Channels - Izotropic will launch a podcast series to discuss company news and milestones, providing timely commentary on corporate updates and relevant developments in the breast imaging sector [3]. - A dedicated online platform, breastct.com, will be introduced to feature articles about breast CT technology and the company's progress, evolving into a comprehensive educational resource over time [4]. Group 3: Strategic Alignment - The awareness strategy is developed in collaboration with Izotropic's capital markets and industry advisory team, focusing on aligning investor engagement and communications with long-term regulatory and commercialization objectives [5].